Vnitr Lek 2015, 61(1):13-14

HevyLite™ - A new method for detection of monoclonal immunoglobulins - editorial

Jakub Radocha
IV. interní hematologická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph.D.

Received: October 3, 2014; Published: January 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Radocha J. HevyLite™ - A new method for detection of monoclonal immunoglobulins - editorial. Vnitr Lek. 2015;61(1):13-14.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bradwell AR, Carr-Smith HR, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47(4): 673-680. Go to original source...
    2. Bradwell AR, Harding SJ, Fourrier NJ et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009; 55(9): 1646-1655. Go to original source... Go to PubMed...
    3. Boyle EM, Fouquet G, Guidez S et al. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer 2014; 120(24): 3952-3957. Go to original source... Go to PubMed...
    4. Koulieris E, Panayiotidis P, Harding SJ et al. Ratio of involved/uninvolved immunoglobulin quantification by HevyliteTM assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol 2012; 1(1): 9. Dostupné z: DOI: <http://doi:10.1186/2162-3619-1-9 >. Go to original source... Go to PubMed...
    5. Bradwell AR, Harding SJ, Fourrier N et al. Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia 2013; 27(1): 202-207. Go to original source... Go to PubMed...
    6. Katzmann JA, Clark R, Kyle RA et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013; 27(1): 208-212. Go to original source... Go to PubMed...
    7. Paiva B, Martinez-Lopez J, Vidriales MB et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29(12): 1627-1633. Go to original source... Go to PubMed...
    8. Ludwig H, Miloslavljevic D, Zojer N et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013; 27(1): 213-219. Go to original source... Go to PubMed...
    9. Ščudla V, Pika T, Minařík J. Význam vyšetření párů těžkých/lehkých řetězců imunoglobulinu u monoklonálních gamapatií. Vnitř Lék 2015; 61(1): 59-70.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.